Search Within

Gastrointestinal Oncology Service

Formats
  1. Journal Article (2349)
  2. Meeting Abstract (1870)
  3. Review (150)
  4. Book Section (127)
  5. Editorial (100)
  6. Guidelines (39)
  7. Correspondence (34)
  8. Conference Paper (24)
  9. Miscellaneous (22)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Solid Tumor Oncology Division (4744)
  2. Department of Medicine (4742)
  3. Center for Pancreatic Cancer Research (2312)
  4. Surgery (1065)
  5. Survivorship Research (1013)
  6. Epidemiology and Biostatistics (842)

More Groups

People
  1. Eileen O'Reilly (803)
  2. Leonard Saltz (796)
  3. Ghassan Abou-Alfa (583)
  4. Nancy Kemeny (545)
  5. David Kelsen (538)
  6. David Ilson (443)

More People

Years
  1. 2025 (219)
  2. 2024 (309)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1290)
  2. Annals of Oncology (331)
  3. Annals of Surgical Oncology (147)
  4. Cancer (128)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1379)
  2. Oxford University Press (462)
  3. Elsevier Inc. (408)
  4. Springer (320)
  5. American Association for Cancer Research (281)
  6. Wiley Blackwell (241)

More Publishers

Results (4744)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The SHARON trial: A study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation
    Meeting Abstract

    Yu, K. H.; Weekes, C. D.; Chen, Y. B. A.; Glazier, J. A.; Glazier, A.; Dahi, P.; Giralt, S.; O'Reilly, E. M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study
    Meeting Abstract

    Park, W.; O'Reilly, E. M.; Furuse, J.; Li, C. P.; Oh, D. Y.; Garcia-Carbonero, R.; Roth, G.; Lee, H. J.; Bhattacharya, P. P.; Moran, D. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) and biomarker assessments in daNIS-3, a phase II platform study of NIS793 (anti–TGF-β monoclonal antibody) and other investigational drug combinations with standard of care (SOC) vs SOC alone in patients (pts) with second-line metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Kopetz, S.; Kasper, S.; Rivera, F.; Tournigand, C.; Cheng, Y.; Deshpande, P.; D'Alessio, D.; Amirouchene Angelozzi, N.; Bento Pereira da Silva, A.; Segal, N. H.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update
    Meeting Abstract

    Segal, N. H.; Pelster, M.; Girda, E.; Fong, L.; Olszanski, A. J.; Han, H.; Casey, K. A.; Li, S.; Welf, E.; Chen, C. I.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • RELATIVITY-106: A phase 1/2 trial of nivolumab (NIVO) + relatlimab (RELA) in combination with bevacizumab (BEV) in first-line (1L) hepatocellular carcinoma (HCC)
    Meeting Abstract

    Sangro, B.; Yau, T.; Harding, J. J.; Acosta Rivera, M.; Kazushi, N.; El-Khoueiry, A. B.; Cruz-Correa, M.; Perez-Callejo, D.; McLean, S.; Sparks, J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • First in human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor (FGFRi), in patients (pts) with advanced cholangiocarcinoma (CCA) and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Meeting Abstract

    Harding, J. J.; Perez, C. A.; Kato, S.; Sharma, M.; Garmezy, B.; Quah, C. S.; Tam, B.; Severson, P.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genetic profiling analysis design of well-differentiated aggressive grade 2 and 3 gastroenteropancreatic neuroendocrine tumors in the phase III randomized controlled COMPOSE trial
    Meeting Abstract

    Halfdanarson, T. R.; Capdevila, J.; Halperin, D. M.; Herrmann, K.; Kong, G.; Leyden, S.; Mailman, J.; Reidy-Lagunes, D.; Srirajaskanthan, R.; Erdö, M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Meeting Abstract

    Wainberg, Z. A.; Melisi, D.; Macarulla, T.; Pazo-Cid, R.; Chandana, S. R.; De La Fouchardiere, C.; Dean, Andrew P.; Kiss, I.; Lee, W.; Goetze, T. O.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress
    Meeting Abstract

    Bekaii-Saab, T. S.; Van Cutsem, E.; Tabernero, J.; Siena, S.; Yoshino, T.; Nakamura, Y.; Raghav, K. P. S.; Cercek, A.; Heinemann, V.; Adelberg, D. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC)
    Meeting Abstract

    Lyman, J. P.; Cabanski, C. R.; Maddock, S.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Rahma, O. E.; Fisher, G. A.; Gabriel, P. E.; Doucette, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save